CA1336687C - Mode de preparation de comprimes contenant de l'ibuprofene, de l'acetaminophere et de la cafeine, les produits ainsi obtenue et leurs applications - Google Patents

Mode de preparation de comprimes contenant de l'ibuprofene, de l'acetaminophere et de la cafeine, les produits ainsi obtenue et leurs applications

Info

Publication number: CA1336687C
Authority: CA; Canada
Prior art keywords: caffeine; tablets; tablet; ibuprofen; apap
Prior art date: 1989-08-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA000609161A

Other languages

English (en)

Inventor

Thomas M. Tencza

Chung Bin Kim

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bristol Myers Squibb Co

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-08-23

Filing date

1989-08-23

Publication date

1995-08-15

1989-08-23 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

1989-08-23 Priority to CA000609161A priority Critical patent/CA1336687C/fr

1995-08-15 Application granted granted Critical

1995-08-15 Publication of CA1336687C publication Critical patent/CA1336687C/fr

2012-08-15 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 title claims abstract description 126
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 title claims abstract description 87
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 title claims abstract description 71
229960001680 ibuprofen Drugs 0.000 title claims abstract description 71
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 title claims abstract description 63
229960001948 caffeine Drugs 0.000 title claims abstract description 63
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 title claims abstract description 63
238000000034 method Methods 0.000 title claims abstract description 22
230000008569 process Effects 0.000 title claims abstract description 15
238000004519 manufacturing process Methods 0.000 title claims abstract description 8
239000000203 mixture Substances 0.000 claims abstract description 33
238000005550 wet granulation Methods 0.000 claims abstract description 16
229960005489 paracetamol Drugs 0.000 claims abstract description 14
206010037660 Pyrexia Diseases 0.000 claims abstract description 4
230000004054 inflammatory process Effects 0.000 claims abstract description 4
238000005469 granulation Methods 0.000 claims description 52
230000003179 granulation Effects 0.000 claims description 52
239000004480 active ingredient Substances 0.000 claims description 30
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 14
239000007888 film coating Substances 0.000 claims description 7
238000009501 film coating Methods 0.000 claims description 7
229920000642 polymer Polymers 0.000 claims description 7
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
239000001856 Ethyl cellulose Substances 0.000 claims description 2
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
235000019325 ethyl cellulose Nutrition 0.000 claims description 2
229920001249 ethyl cellulose Polymers 0.000 claims description 2
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
229920001223 polyethylene glycol Polymers 0.000 claims description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
239000004615 ingredient Substances 0.000 abstract description 13
208000029618 autoimmune pulmonary alveolar proteinosis Diseases 0.000 abstract 1
239000003826 tablet Substances 0.000 description 120
238000004090 dissolution Methods 0.000 description 28
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 21
229960001138 acetylsalicylic acid Drugs 0.000 description 19
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 18
239000002245 particle Substances 0.000 description 17
229920000036 polyvinylpyrrolidone Polymers 0.000 description 13
230000000202 analgesic effect Effects 0.000 description 12
238000007907 direct compression Methods 0.000 description 12
229920002472 Starch Polymers 0.000 description 11
235000021355 Stearic acid Nutrition 0.000 description 11
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 11
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 11
239000008107 starch Substances 0.000 description 11
235000019698 starch Nutrition 0.000 description 11
229940032147 starch Drugs 0.000 description 11
239000008117 stearic acid Substances 0.000 description 11
229940069328 povidone Drugs 0.000 description 10
239000000843 powder Substances 0.000 description 10
229920002261 Corn starch Polymers 0.000 description 9
229920000168 Microcrystalline cellulose Polymers 0.000 description 9
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
239000008120 corn starch Substances 0.000 description 9
229940016286 microcrystalline cellulose Drugs 0.000 description 9
235000019813 microcrystalline cellulose Nutrition 0.000 description 9
239000008108 microcrystalline cellulose Substances 0.000 description 9
239000000243 solution Substances 0.000 description 8
238000012360 testing method Methods 0.000 description 7
239000000463 material Substances 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
239000007921 spray Substances 0.000 description 6
239000011248 coating agent Substances 0.000 description 5
238000000576 coating method Methods 0.000 description 5
229960000913 crospovidone Drugs 0.000 description 5
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 5
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 4
239000004698 Polyethylene Substances 0.000 description 4
229920001213 Polysorbate 20 Polymers 0.000 description 4
LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 4
239000002518 antifoaming agent Substances 0.000 description 4
239000011230 binding agent Substances 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
238000002156 mixing Methods 0.000 description 4
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
239000002253 acid Substances 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000012530 fluid Substances 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000008187 granular material Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
229960004063 propylene glycol Drugs 0.000 description 3
235000013772 propylene glycol Nutrition 0.000 description 3
238000003860 storage Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000004793 Polystyrene Substances 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical group O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
238000000889 atomisation Methods 0.000 description 2
230000008859 change Effects 0.000 description 2
239000008199 coating composition Substances 0.000 description 2
229940099112 cornstarch Drugs 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000007908 dry granulation Methods 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000007941 film coated tablet Substances 0.000 description 2
229920001903 high density polyethylene Polymers 0.000 description 2
239000004700 high-density polyethylene Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
-1 polymethylsiloxane Polymers 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
229920002785 Croscarmellose sodium Polymers 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
239000013543 active substance Substances 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000007767 bonding agent Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
229940124827 caffeine tablet Drugs 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000005056 compaction Methods 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
239000013078 crystal Substances 0.000 description 1
MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical group OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical group O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000011978 dissolution method Methods 0.000 description 1
238000007922 dissolution test Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000005496 eutectics Effects 0.000 description 1
229940085392 excedrin Drugs 0.000 description 1
239000010408 film Substances 0.000 description 1
238000005755 formation reaction Methods 0.000 description 1
238000009499 grossing Methods 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
230000003993 interaction Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000003020 moisturizing effect Effects 0.000 description 1
230000003387 muscular Effects 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
239000000820 nonprescription drug Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229940068977 polysorbate 20 Drugs 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
229940083037 simethicone Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
229950006451 sorbitan laurate Drugs 0.000 description 1
235000011067 sorbitan monolaureate Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
238000013112 stability test Methods 0.000 description 1
238000012430 stability testing Methods 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

Health & Medical Sciences (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

CA000609161A 1989-08-23 1989-08-23 Mode de preparation de comprimes contenant de l'ibuprofene, de l'acetaminophere et de la cafeine, les produits ainsi obtenue et leurs applications Expired - Fee Related CA1336687C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000609161A CA1336687C (fr)	1989-08-23	1989-08-23	Mode de preparation de comprimes contenant de l'ibuprofene, de l'acetaminophere et de la cafeine, les produits ainsi obtenue et leurs applications

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA000609161A CA1336687C (fr)	1989-08-23	1989-08-23	Mode de preparation de comprimes contenant de l'ibuprofene, de l'acetaminophere et de la cafeine, les produits ainsi obtenue et leurs applications

Publications (1)

Publication Number	Publication Date
CA1336687C true CA1336687C (fr)	1995-08-15

Family

ID=4140485

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000609161A Expired - Fee Related CA1336687C (fr)	1989-08-23	1989-08-23	Mode de preparation de comprimes contenant de l'ibuprofene, de l'acetaminophere et de la cafeine, les produits ainsi obtenue et leurs applications

Country Status (1)

Country	Link
CA (1)	CA1336687C (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006004449A3 (fr) *	2004-07-07	2006-03-02	Aft Pharmaceuticals Ltd	Composition combinee
US7320985B2 (en)	1997-02-04	2008-01-22	Senju Pharmaceutical Co., Ltd.	Method for stabilizing arylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized arylcarboxylic acid
WO2010044681A1 (fr) *	2008-10-14	2010-04-22	Aft Pharmaceuticals Limited	Produit médicamenteux et traitement associé
US8580856B2 (en)	2006-10-20	2013-11-12	Ncneil-Ppc, Inc.	Acetaminophen/ibuprofen combinations and method for their use
WO2016030091A1 (fr) *	2014-08-28	2016-03-03	Boehringer Ingelheim International Gmbh	Comprimés pelliculés pour le traitement de la douleur aiguë
EP3185861A1 (fr) *	2014-08-28	2017-07-05	Sanofi-Aventis Deutschland GmbH	Composition pharmaceutique pour le traitement de la douleur aiguë des dents ou des mâchoires
US11197830B2 (en)	2019-02-27	2021-12-14	Aft Pharmaceuticals Limited	Pharmaceutical composition containing acetaminophen and ibuprofen

1989
- 1989-08-23 CA CA000609161A patent/CA1336687C/fr not_active Expired - Fee Related

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7320985B2 (en)	1997-02-04	2008-01-22	Senju Pharmaceutical Co., Ltd.	Method for stabilizing arylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized arylcarboxylic acid
RU2455983C1 (ru) *	2004-07-07	2012-07-20	АФТ Фармасьютикалз Лимитед	Комбинированная композиция
GB2431346A (en) *	2004-07-07	2007-04-25	Aft Pharmaceuticals Ltd	A combination composition
AU2005260243B2 (en) *	2004-07-07	2009-10-29	Aft Pharmaceuticals Limited	A combination composition
GB2431346B (en) *	2004-07-07	2010-01-27	Aft Pharmaceuticals Ltd	A combination composition comprising paracetamol and ibuprofen
US10532036B2 (en)	2004-07-07	2020-01-14	Aft Pharmaceuticals Limited	Combination composition
WO2006004449A3 (fr) *	2004-07-07	2006-03-02	Aft Pharmaceuticals Ltd	Composition combinee
US8580856B2 (en)	2006-10-20	2013-11-12	Ncneil-Ppc, Inc.	Acetaminophen/ibuprofen combinations and method for their use
US8580855B2 (en) *	2006-10-20	2013-11-12	Mcneil-Ppc, Inc.	Acetaminophen / ibuprofen combinations and method for their use
GB2476418B (en) *	2008-10-14	2013-04-24	Aft Pharmaceuticals Ltd	A medicinal product and treatment
RU2487707C2 (ru) *	2008-10-14	2013-07-20	АФТ Фармасьютикалз Лимитед	Применение парацетамола и ибупрофена в лечении
GB2476418A (en) *	2008-10-14	2011-06-22	Aft Pharmaceuticals Ltd	A medicinal product and treatment
WO2010044681A1 (fr) *	2008-10-14	2010-04-22	Aft Pharmaceuticals Limited	Produit médicamenteux et traitement associé
CN107106502A (zh) *	2014-08-28	2017-08-29	赛诺菲-安万特德国有限公司	用于治疗急性疼痛的薄膜包衣片
EP3185861A1 (fr) *	2014-08-28	2017-07-05	Sanofi-Aventis Deutschland GmbH	Composition pharmaceutique pour le traitement de la douleur aiguë des dents ou des mâchoires
WO2016030091A1 (fr) *	2014-08-28	2016-03-03	Boehringer Ingelheim International Gmbh	Comprimés pelliculés pour le traitement de la douleur aiguë
AU2015309175B2 (en) *	2014-08-28	2020-09-03	Sanofi-Aventis Deutschland Gmbh	Film coated tablet for the treatment of acute pain
US11197830B2 (en)	2019-02-27	2021-12-14	Aft Pharmaceuticals Limited	Pharmaceutical composition containing acetaminophen and ibuprofen
US11534407B2 (en)	2019-02-27	2022-12-27	Aft Pharmaceuticals Limited	Pharmaceutical compostion containing acetominophen and ibuprofen
US11872317B2 (en)	2019-02-27	2024-01-16	Aft Pharmaceuticals Limited	Pharmaceutical composition containing acetominophen and ibuprofen
US12194151B2 (en)	2019-02-27	2025-01-14	Aft Pharmaceuticals Limited	Pharmaceutical compostion containing acetominophen and ibuprofen

Legal Events

Date	Code	Title	Description
2004-08-16	MKLA	Lapsed

Publication	Publication Date	Title
AU639334B2 (en)	1993-07-22	Taste masking and sustained release coatings for pharmaceuticals
AU2006250340B2 (en)	2012-02-09	Pharmaceutical composition
US5215755A (en)	1993-06-01	Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
US4562024A (en)	1985-12-31	Process for preparing granulate containing poorly compressible medicinally active matter
EP0345787B1 (fr)	1992-11-11	Médicament en association avec un agent masquant le goût et son procédé de fabrication
HRP20040996A2 (en)	2005-06-30	High drug load tablet
NL8500724A (nl)	1986-10-01	Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan.
HUE031153T2 (en)	2017-07-28	A solid pharmaceutical dosage form comprising an HIV protease inhibitor solid dispersion
AU2005320362A1 (en)	2006-07-06	Controlled release complex formulation for oral administration of medicine for diabetes and method for the preparation thereof
HU190619B (en)	1986-09-29	Process for producing tablets with controlled dissolution of active ingredients
JP3491887B2 (ja)	2004-01-26	糖アルコール造粒物集合体の製法
CA1336687C (fr)	1995-08-15	Mode de preparation de comprimes contenant de l'ibuprofene, de l'acetaminophere et de la cafeine, les produits ainsi obtenue et leurs applications
US5087454A (en)	1992-02-11	Ibuprofen tablet
CA2637925A1 (fr)	2007-08-02	Formulations de levetiracetam et leurs procedes de preparation
US5358717A (en)	1994-10-25	Directly-compressible naproxen or naproxen sodium compositions
EP2471520B1 (fr)	2016-04-20	Compositions pharmaceutiques de lévétiracetam
JP4400941B2 (ja)	2010-01-20	漢方含有錠剤および漢方充填カプセル剤および生薬含有錠剤および生薬充填カプセル剤および漢方含有錠剤の製造方法および漢方充填カプセル剤の製造方法および生薬含有錠剤の製造方法および生薬充填カプセル剤の製造方法
US20100055177A1 (en)	2010-03-04	Modified release composition of levetiracetam and process for the preparation thereof
JP2003277266A (ja)	2003-10-02	分配用混合粉体、及びそれを使用した錠剤またはカプセル
JP4591726B2 (ja)	2010-12-01	メキタジン含有内服固形製剤
JP2000516601A (ja)	2000-12-12	水溶性化合物及びセルロースを含有する粒状物
KR20060119860A (ko)	2006-11-24	용해성과 유동성을 개선한 의약 조성물
JPH02286614A (ja)	1990-11-26	アセトアミノフェン製剤
IL138950A (en)	2006-08-20	Stable compositions comprising levosimendan and alginic acid
JP6106359B2 (ja)	2017-03-29	ロキソプロフェンナトリウムとビタミンｂ１を含有する固形製剤